Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases
Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy? At the recently Infectious Disease Week (IDWeek 2023), "Infectious Disease Frontline" invited Dr. Thomas L. Holland from Duke University Medical Center to introduce the practical application and potential challenges of DOOR research on ordinal outcome, and shared its importance to future clinical trials and treatment plans.
